Preclinical study validates HILO WAVE Dual Hyaluronic Acid Complex regenerative mechanism

HIGHER Corporation published a peer-reviewed preclinical study in the International Journal of Molecular Sciences validating the regenerative mechanism of its HILO WAVE Dual-HA Technology (DHC). The research, led by the Department of Dermatology at Yonsei University Severance Hospital, showed that this dual hyaluronic acid complex maintains stable fibroblast viability and increases extracellular matrix activity in animal models. The data also demonstrated enhanced antioxidant capacity and improved skin barrier-related markers without triggering significant inflammatory responses. For your clinic, this provides a solid, evidence-based argument for patients seeking skin quality improvement without the downtime associated with inflammatory-driven remodeling. It positions the booster as a highly biocompatible option for regenerative protocols. To see how these preclinical findings translate to actual patient outcomes, you can access the HILO WAVE Global Webinar scheduled for August 12, 2026. The session will feature clinical protocols and an interactive Q&A session with Dr. Kyung Tae Bae, which should help you assess whether to integrate this technology into your treatment menu once it becomes widely available in your market.

Source: PR Newswire Asia, https://www.prnasia.com/story/45452-0.shtml